Expression of concern
Antitumor Activity of Sorafenib in Human Cancer Cell Lines with Acquired Resistance to EGFR and VEGFR Tyrosine Kinase Inhibitors
Paper Information
Record ID:
20310
Author(s):
Publication Date:
December 09, 2011
Retraction Date:
April 11, 2019
(6.6 years years ago)
Subjects:
Country:
🇮🇹 ItalyArticle Type:
Publisher:
PLoS
Open Access:
Yes
PubMed ID:
Retraction PubMed ID:
Expression of concern Details
Retraction Reasons:
Nature of Retraction:
Expression of concern
Retraction Notice:
10.1371/journal.pone.0215109Additional Notes:
see also: https://pubpeer.com/publications/ECAE674D2B96F98DF26BDC250EA222;
Citations (39)
39
Total Citations13
Post-Retraction(33.3%)
25
Pre-Retraction1
Same DayPost-Retraction Citation Analysis
0
Within 30 days
2
Within 1 year
10
After 2+ years
1797
Days since retraction (latest)
Synthesis of Sorafenib−Ruthenium Complexes, Investigation of Biological Activities and Applications in Drug Delivery Systems as an Anticancer Agent
Belma Zengin Kurt, Dilek Öztürk Civelek, Elmas Begüm Çakmak et al. (8 authors)
Journal of Medicinal Chemistry
Open Access
Published: Mar 2024
20 citations
20 citations
1797 days after retraction
Exploring the potential of EphA2 receptor signaling pathway: a comprehensive review in cancer treatment
Mohd Nehal, Jahanarah Khatoon, Salman Akhtar et al. (4 authors)
Molecular Biology Reports
Published: Feb 2024
6 citations
6 citations
1779 days after retraction
Retraction: Antitumor Activity of Sorafenib in Human Cancer Cell Lines with Acquired Resistance to EGFR and VEGFR Tyrosine Kinase Inhibitors
Unknown Authors
PLoS ONE
Open Access
Published: Jan 2024
1750 days after retraction
Targeted co-delivery of PD-L1 monoclonal antibody and sorafenib to circulating tumor cells via platelet-functionalized nanocarriers
Xuanbo Da, Jiantao Mo, Qiao‐Xin Li et al. (9 authors)
Biochemical and Biophysical Research Communications
Published: Jun 2023
11 citations
11 citations
1521 days after retraction
Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition
Tian Li, Shi Hu
Elsevier eBooks
Published: Jan 2023
69 citations
69 citations
1361 days after retraction
Single-Cell FISH Analysis Reveals Distinct Shifts in PKM Isoform Populations during Drug Resistance Acquisition
Seong Ho Kim, Ji Hun Wi, HyeRan Gwak et al. (5 authors)
Biomolecules
Open Access
Published: Aug 2022
2 citations
2 citations
1213 days after retraction
LC-MS/MS monitoring of the colorectal carcinoma cellular uptake and entrapment of sorafenib and its N-oxide active metabolite
Tarek Elawady, Ahmed M. Al‐Abd, Alaa Khedr et al. (5 authors)
Journal of Pharmaceutical and Biomedical Analysis
Published: Feb 2022
3 citations
3 citations
1048 days after retraction
Analysis of drug-induced hand–foot syndrome using a spontaneous reporting system database
Yu Yoshida, Sayaka Sasaoka, Mizuki Tanaka et al. (15 authors)
Therapeutic Advances in Drug Safety
Open Access
Published: Jan 2022
5 citations
5 citations
996 days after retraction
Identification of modules based on integrative analysis for drug prediction in colorectal cancer
Fatemeh Akbari, Maryam Peymani, Ali Salehzadeh et al. (4 authors)
Gene Reports
Published: Oct 2021
2 citations
2 citations
931 days after retraction
Isatin-Hydrazones with Multiple Receptor Tyrosine Kinases (RTKs) Inhibitory Activity and In-Silico Binding Mechanism
Huda Salem AlSalem, Md. Arifuzzaman, Iman S. Issa et al. (4 authors)
Applied Sciences
Open Access
Published: Apr 2021
17 citations
17 citations
741 days after retraction
Synthesis, anticancer activity, and β‐lactoglobulin binding interactions of multitargeted kinase inhibitor sorafenib tosylate (SORt) using spectroscopic and molecular modelling approaches
Hamid Tanzadehpanah, Asrin Bahmani, Neda Hosseinpour Moghadam et al. (7 authors)
Luminescence
Published: Jul 2020
19 citations
19 citations
475 days after retraction
RAS and BRAF in the foreground for non-small cell lung cancer and colorectal cancer: Similarities and main differences for prognosis and therapies
Ioanna Giopanou, Alexandros Pintzas
Critical Reviews in Oncology/Hematology
Published: Dec 2019
15 citations
15 citations
251 days after retraction
Knockout of glucosidase II beta subunit inhibits growth and metastatic potential of lung cancer cells by inhibiting receptor tyrosine kinase activities
Worapong Khaodee, Suruk Udomsom, Phraepakaporn Kunnaja et al. (4 authors)
Scientific Reports
Open Access
Published: Jul 2019
10 citations
10 citations
97 days after retraction
Expression of Concern: Antitumor Activity of Sorafenib in Human Cancer Cell Lines with Acquired Resistance to EGFR and VEGFR Tyrosine Kinase Inhibitors
Unknown Authors
PLoS ONE
Open Access
Published: Apr 2019
1 citation
1 citation
Same day as retraction
Caveolin-1 Inhibits Proliferation, Migration, and Invasion of Human Colorectal Cancer Cells by Suppressing Phosphorylation of Epidermal Growth Factor Receptor
Juan‐Li Yang, Tienian Zhu, Ruijing Zhao et al. (7 authors)
Medical Science Monitor
Open Access
Published: Jan 2018
28 citations
28 citations
449 days before retraction
Synthesis, antitumour and antioxidant activities of novel α,β-unsaturated ketones and related heterocyclic analogues: EGFR inhibition and molecular modelling study
Walaa M. El-Husseiny, Magda A.‐A. El‐Sayed, Naglaa I. Abdel-Aziz et al. (6 authors)
Journal of Enzyme Inhibition and Medicinal Chemistry
Open Access
Published: Jan 2018
40 citations
40 citations
465 days before retraction
Bromelain has significant clinical benefits after extraction of the third molar during chemotherapy in patients with hematologic tumor
Yi Quan Tan, Ping Li
Oncology Letters
Open Access
Published: Dec 2017
12 citations
12 citations
477 days before retraction
Targeted Therapy for Medullary Thyroid Cancer: A Review
S. R. Priya, Chandra Shekhar Dravid, Raghunadharao Digumarti et al. (4 authors)
Frontiers in Oncology
Open Access
Published: Oct 2017
47 citations
47 citations
552 days before retraction
Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer
Meng Li, Jingyu Yang, Wenlong Zhou et al. (13 authors)
British Journal of Cancer
Open Access
Published: Aug 2017
65 citations
65 citations
590 days before retraction
Simultaneous inhibition of growth and metastasis of hepatocellular carcinoma by co-delivery of ursolic acid and sorafenib using lactobionic acid modified and pH-sensitive chitosan-conjugated mesoporous silica nanocomplex
Ruirui Zhao, Tao Li, Guirong Zheng et al. (6 authors)
Biomaterials
Open Access
Published: Jul 2017
185 citations
185 citations
628 days before retraction
YM155 Reverses Statin Resistance in Renal Cancer by Reducing Expression of Survivin
Takashi Nitta, Hidekazu Koike, Takeshi Miyao et al. (8 authors)
Anticancer Research
Open Access
Published: Jan 2017
7 citations
7 citations
830 days before retraction
Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK
Erika Martinelli, Floriana Morgillo, Teresa Troiani et al. (4 authors)
Cancer Treatment Reviews
Published: Dec 2016
143 citations
143 citations
832 days before retraction
The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer
Poupak Fallahi, Silvia Martina Ferrari, Enke Baldini et al. (8 authors)
Expert Review of Anticancer Therapy
Open Access
Published: Sep 2016
26 citations
26 citations
932 days before retraction
Selective use of vandetanib in the treatment of thyroid cancer
Alessandro Antonelli, Poupak Fallahi, Flavia Di Bari et al. (8 authors)
Drug Design Development and Therapy
Open Access
Published: Jul 2015
32 citations
32 citations
1380 days before retraction
Expression of caveolin-1 is correlated with lung adenocarcinoma proliferation, migration, and invasion
Tian-Yan Luan, Tienian Zhu, Yujie Cui et al. (11 authors)
Medical Oncology
Published: Jun 2015
19 citations
19 citations
1391 days before retraction
Progress in Discovery of KIF5B-RET Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer
Minsoo Song
Journal of Medicinal Chemistry
Published: Jan 2015
45 citations
45 citations
1535 days before retraction
Design, microwave-mediated synthesis and biological evaluation of novel 4-aryl(alkyl)amino-3-nitroquinoline and 2,4-diaryl(dialkyl)amino-3-nitroquinolines as anticancer agents
Monika Chauhan, Anil Rana, Jimi Marin Alex et al. (6 authors)
Bioorganic Chemistry
Published: Nov 2014
25 citations
25 citations
1606 days before retraction
Silencing of Suppressor of Cytokine Signaling-3 due to Methylation Results in Phosphorylation of STAT3 in Imatinib Resistant BCR-ABL Positive Chronic Myeloid Leukemia Cells
Hamid Ali Nagi Al‐Jamal, Siti Asmaa Mat Jusoh, Ang Cheng Yong et al. (6 authors)
Asian Pacific Journal of Cancer Prevention
Open Access
Published: Jun 2014
24 citations
24 citations
1761 days before retraction
YM155 reverses rapamycin resistance in renal cancer by decreasing survivin
Hidekazu Koike, Takashi Nitta, Yoshitaka Sekine et al. (11 authors)
Journal of Cancer Research and Clinical Oncology
Published: Jun 2014
22 citations
22 citations
1766 days before retraction
Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition
Teresa Troiani, Stefania Napolitano, Donata Vitagliano et al. (10 authors)
Clinical Cancer Research
Open Access
Published: May 2014
3 citations
3 citations
1798 days before retraction
Tumor Microenvironment, Angiogenesis Biology, and Targeted Therapy
John V. Heymach, Tina Cascone
Lung Cancer
Published: Apr 2014
1833 days before retraction
Sphingosine Kinase-1 Activation Causes Acquired Resistance Against Sunitinib in Renal Cell Carcinoma Cells
Hui Gao, Lichun Deng
Cell Biochemistry and Biophysics
Published: Aug 2013
28 citations
28 citations
2059 days before retraction
Inhibition of related <scp>JAK</scp>/<scp>STAT</scp> pathways with molecular targeted drugs shows strong synergy with ruxolitinib in chronic myeloproliferative neoplasm
Santiago Barrio, Miguel Gallardo, Alicia Arenas et al. (11 authors)
British Journal of Haematology
Published: Apr 2013
23 citations
23 citations
2197 days before retraction
Activated RET and ROS: two new driver mutations in lung adenocarcinoma.
Marc Bos, Masyar Gardizi, Hans‐Ulrich Schildhaus et al. (5 authors)
PubMed
Published: Apr 2013
16 citations
16 citations
2201 days before retraction
Sunitinib Reverse Multidrug Resistance in Gastric Cancer Cells by Modulating Stat3 and Inhibiting P-gp Function
Ye Zhang, Qiong Wang
Cell Biochemistry and Biophysics
Published: Mar 2013
24 citations
24 citations
2226 days before retraction
Vandetanib for the Treatment of Medullary Thyroid Cancer
Nicole G. Chau, Robert I. Haddad
Clinical Cancer Research
Open Access
Published: Dec 2012
84 citations
84 citations
2311 days before retraction
Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors
Matteo Simonelli, Paolo Andrea Zucali, Elena Lorenzi et al. (18 authors)
European Journal of Cancer
Published: Nov 2012
13 citations
13 citations
2344 days before retraction
YM155 Reverses Cisplatin Resistance in Head and Neck Cancer by Decreasing Cytoplasmic Survivin Levels
Bhavna Kumar, Arti Yadav, James C. Lang et al. (8 authors)
Molecular Cancer Therapeutics
Open Access
Published: Jun 2012
72 citations
72 citations
2484 days before retraction
Efficacy and Tolerability of Pharmacotherapy Options for the Treatment of Medullary Thyroid Cancer
Hari A. Deshpande, Khushboo Sheth, Julie Ann Sosa et al. (4 authors)
Clinical Medicine Insights Oncology
Open Access
Published: Jan 2012
5 citations
5 citations
2657 days before retraction
Related Records
This article has multiple records in the database due to different notices:
Record #54270
Jan 25, 2024Quick Stats
Total Citations:
39
Years Since Retraction:
6.6 years
Open Access:
Yes
Last Checked:
Never